Our journey to successful gene therapy for Hemophilia B

Human Gene Therapy

Volumn 25, Issue 11, 2014, Pages 923-926

  Nathwani, Amit C ^a,b,c   Nienhuis, Arthur W ^d   Davidoff, Andrew M ^d  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; LIVER ENZYME; PARVOVIRUS VECTOR;

ANTIBODY PRODUCTION; BLEEDING TENDENCY; BLOOD CLOTTING; CODON; GENE THERAPY; GENE TRANSFER; HEMOPHILIA B; HUMAN; NONHUMAN; REVIEW; STABLE EXPRESSION; ANIMAL; DEPENDOPARVOVIRUS; GENETIC TRANSDUCTION; GENETICS;

ANIMALS; DEPENDOVIRUS; FACTOR IX; GENETIC THERAPY; HEMOPHILIA B; HUMANS; TRANSDUCTION, GENETIC;

EID: 84910633509     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.2540     Document Type: Review

References (33)

1. Allay, J.A., Sleep, S., Long, S., et al. (2011). Good manufacturing practice production of self-complementary serotype 8 adenoassociated viral vector for a hemophilia B clinical trial. Hum. Gene Ther. 22, 595-604.
2. Blacklow, N.R., Hoggan, M.D., and Rowe, W.P. (1968). Serologic evidence for human infection with adenovirusassociated viruses. J. Natl. Cancer Inst. 40, 319-327.
3. Darby, S.C., Kan, S.W., Spooner, R.J., et al. (2007). Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 110, 815-825.
4. Davidoff, A.M., Gray, J.T., Ng, C.Y., et al. (2005). Comparison of the ability of adeno-Associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol. Ther. 11, 875-888.
5. Davidoff, A.M., Ng, C.Y., Sleep, S., et al. (2004). Purification of recombinant adeno-Associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J. Virol. Methods 121, 209-215.
6. Donahue, R.E., and Dunbar, C.E. (2001). Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells. Hum. Gene Ther. 12, 607-617.
7. Gao, G.P., Alvira, M.R., Wang, L., et al. (2002). Novel adeno-Associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 11854-11859.
8. Grimm, D., Zhou, S., Nakai, H., et al. (2003). Preclinical in vivo evaluation of pseudotyped adeno-Associated virus vectors for liver gene therapy. Blood 102, 2412-2419.
9. Hagstrom, J.N., Couto, L.B., Scallan, C., et al. (2000). Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/ promoter. Blood 95, 2536-2542.
10. Herzog, R.W., Hagstrom, J.N., Kung, S.H., et al. (1997). Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adenoassociated virus. Proc. Natl. Acad. Sci. USA 94, 5804-5809.
11. Herzog RW, Yang, E.Y., Couto, L.B., et al. (1999). Long-Term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-Associated viral vector. Nat. Med. 5, 56-63.
12. Hirata, R.K., and Russell, D.W. (2000). Design and packaging of adeno-Associated virus gene targeting vectors. J. Virol. 74, 4612-4620.
13. Kay, M.A., Manno, C.S., Ragni, M.V., et al. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24, 257-261.
14. Lozier, J.N., Metzger, M.E., Donahue, R.E., et al. (1999). Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 94, 3968-3975.
15. Manno, C.S., Chew, A.J., Hutchison, S., et al. (2003). AAVmediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972.
16. Manno, C.S., Arruda, V.R., Pierce, G.F., et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347.
17. McCarty, D.M., Fu, H., Monahan, P.E., et al. (2003). Adenoassociated virus terminal repeat (TR) mutant generates selfcomplementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10, 2112-2118.
18. McIntosh, J., Lenting, P.J., Rosales, C., et al. (2013). Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 121, 3335-3344.
19. Mingozzi, F., Maus, M.V., Hui, D.J., et al. (2007). CD8( +) Tcell responses to adeno-Associated virus capsid in humans. Nat. Med. 13, 419-422.
20. Nathwani, A.C., Hanawa, H., Vandergriff, J., et al. (2000). Efficient gene transfer into human cord blood CD34 + cells and the CD34 + CD38-subset using highly purified recombinant adeno-Associated viral vector preparations that are free of helper virus and wild-Type AAV. Gene Ther. 7, 183-195.
21. Nathwani, A.C., Davidoff, A., Hanawa, H., et al. (2001). Factors influencing in vivo transduction by recombinant adenoassociated viral vectors expressing the human factor IX cDNA. Blood 97, 1258-1265.
22. Nathwani, A.C., Davidoff, A.M., Hanawa, H., et al. (2002). Sustained high-level expression of human factor IX (hFIX) after liver-Targeted delivery of recombinant adeno-Associated virus encoding the hFIX gene in rhesus macaques. Blood 100, 1662-1669.
23. Nathwani, A.C., Gray, J.T., Ng, C.Y., et al. (2006). Selfcomplementary adeno-Associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107, 2653-2661.
24. Nathwani, A.C., Gray, J.T., McIntosh, J., et al. (2007). Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109, 1414-1421.
25. Nathwani, A.C., Rosales, C., McIntosh, J., et al. (2011). Longterm safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol. Ther. 19, 876-885.
26. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., et al. (2011). Adenovirus-Associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365.
27. Parks, W.P., Boucher, D.W., Melnick, J.L., et al. (1970). Seroepidemiological and ecological studies of the adenovirusassociated satellite viruses. Infect. Immun. 2, 716-722.
28. Radcliffe, P.A., Sion, C.J., Wilkes, F.J., et al. (2008). Analysis of factor VIII mediated suppression of lentiviral vector titres. Gene Ther. 15, 289-297.
29. Sarkar, R., Tetreault, R., Gao, G., et al. (2004). Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 103, 1253-1260.
30. Thomas, C.E., Storm, T.A., Huang, Z., and Kay, M.A. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-Associated virus vectors. J. Virol. 78, 3110-3122.
31. Wang, Z., Ma, H.I., Li, J., et al. (2003). Rapid and highly efficient transduction by double-stranded adeno-Associated virus vectors in vitro and in vivo. Gene Ther 10, 2105-2111.
32. Ward, N.J., Buckley, S.M., Waddington, S.N., et al. (2011). Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood 117, 798-807.
33. Yang, G.S., Schmidt, M., Yan, Z., et al. (2002). Virus-mediated transduction of murine retina with adeno-Associated virus: Effects of viral capsid and genome size. J. Virol. 76, 7651-7660.